Cellipont Bioservices

Cellipont offers expert allogeneic cell therapy manufacturing, delivering scalable, high-viability solutions with robust production and supply chain support.

Autologous cell therapies use a patient’s own cells to create personalized treatments for cancer, autoimmune, and rare diseases, requiring individualized manufacturing processes.

Discover Cellipont’s CAR-T services, offering process optimization, analytics, and GMP manufacturing to accelerate your therapy from lab to clinic.

Cellipont offers expert cell therapy GMP manufacturing, integrating process development, QC, regulatory support, and sterile fill/finish for clinical success.

Milpitas, CA and The Woodlands, TX — March 24, 2026 / Cision / – Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced

Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Diakonos Oncology, announced today that they have entered into an agreement for the Process Development & cGMP Manufacturing of DOC1021, an

The WOODLANDS, Texas and Muskego, Wisconsin. — September 9, 2026/ Cision / — Cellipont Bioservices, a leading cell therapy Contract Development and

Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility

Daniel has over 15 years of experience in manufacturing, engineering, and leadership roles in pharmaceutical and contract development and manufacturing organizations (CDMOs). He previously served as Director of Manufacturing Science & Technology for Catalent’s Cell & Gene Therapy division and as Interim Site Head for Catalent’s Microbial & Plasmid Manufacturing.

Denise has over 25 years of experience leading quality assurance, quality control, and validation teams in the pharmaceutical industry, specializing in building scalable quality systems from early clinical stages through licensure and launch.

Jennifer (“JK”) brings over 20 years of experience leading complex projects across the Cell and Gene Therapy landscape — from facility buildouts and commissioning to late-phase technology transfers in the CDMO environment.

Cellipont Bioservices’ leadership team includes industry experts in cell therapy who focus on innovation, operational excellence, and strategic growth.

Cellipont Bioservices is a cell therapy contract development and manufacturing organization (CDMO) with expert teams advancing autologous and allogeneic cell therapies.

Cellipont Bioservices supports cell therapy development and manufacturing with an expert team.

Cellipont Bioservices offers tailored cell therapy development, analytics, and cGMP manufacturing.

Cellipont Bioservices’ Privacy Policy explains how the company collects, uses, and protects personal information in compliance with data regulations.

Kincellis Advanced Therapies emerges from the merger of Kincell Bio and Cellipont Bioservices, forming a scaled U.S. contract development and manufacturing organization (CDMO) for advanced therapies. The new entity expands technical expertise across the full development spectrum, from early-stage research through commercial-scale production. The combination consolidates capabilities to support the growing demand for advanced therapeutic solutions.

Sep 2026BioSpaceNews article

Cellipont Bioservices and Ronawk collaborate to accelerate scalable production of high-quality mesenchymal stem cells (MSCs). The partnership leverages Ronawk’s Bio-OS™ platform to address industry challenges in scalability, consistency, and capital efficiency for cell therapy manufacturing. Both companies aim to enhance therapeutic readiness for MSC-based treatments.

Nov 2025Cellipont BioservicesNews article

Cellipont Bioservices and Optieum Biotechnologies collaborate to advance cGMP manufacturing of a CAR-T therapy targeting glioblastoma. The partnership focuses on scaling production of Optieum’s OPTF01 product, a next-generation CAR-T treatment. This development aims to accelerate clinical progress for patients with this aggressive brain cancer.

May 2025Cellipont BioservicesNews article

Cellipont Bioservices appoints **Darren Head** as Chief Executive Officer, combining his role as Chairman. The company, a cell therapy CDMO, secures a minority growth equity investment from **HealthQuest Capital** to support expansion and operational scaling. Head’s biopharmaceutical leadership strengthens Cellipont’s focus on advancing cell therapy manufacturing solutions.

Oct 2024Cellipont BioservicesNews article